We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cardium Appoints CMO to Lead Generx™ Development Program

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Cardium Appoints CMO to Lead Generx™ Development Program"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Cardium Therapeutics, Inc. has announced the appointment of Randall W. Moreadith, M.D., Ph.D. as Executive Vice President and Chief Medical Officer.

"We are very pleased to welcome Dr. Randall Moreadith to Cardium's executive management team," said Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics.

"He assumes a key leadership position in our company to accelerate the late-stage clinical development of our lead product candidate, Generx, and to seek out promising corporate development opportunities."

Dr. Moreadith added, "I am very excited about joining Cardium's talented team and look forward to contributing to its future growth and success."

Before joining Cardium, Dr. Moreadith served as Chief Medical Officer of Renovis, Inc. Previously, he was co-founder, President and Chief Operating Officer of ThromboGenics Ltd., and served as Principal Medical Officer of Quintiles, Inc. where he co-founded Quintiles' Cardiovascular Therapeutics Group.

He received his M.D. from Duke University and his Ph.D. from Johns Hopkins University, and was a Howard Hughes Medical Institute Postdoctoral Fellow in Genetics at Harvard Medical School.

His faculty appointments include the University of Texas Southwestern Medical Center, where he was an Established Investigator of the American Heart Association.